Auxilium Pharmaceuticals, Inc. Announces Positive Top-line Data from XIAFLEX …

Auxilium Pharmaceuticals, Inc. Announces Positive Top-line Data from XIAFLEX …
The phase IIa study was an open-label, controlled dose-ranging study designed to assess the safety and efficacy of CCH for the treatment of Stage 2 unilateral idiopathic FSS in comparison to an exercise-only control group. The study involved 50 …
Read more on SYS-CON Media (press release)